INmune Bio files EMA packages for Ebstrocel in rare skin disease

INmune Bio has filed two regulatory packages with the European Medicines Agency for Ebstrocel, its mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The NASDAQ-listed company submitted an orphan drug designation application and a pre-MAA scientific advice request, both intended to smooth the path toward a full Marketing Authorisation Application in Q1 2027.

RDEB is a severe, life-limiting genetic disorder in which a defect in collagen VII production causes extreme skin fragility, chronic wounds and progressive systemic complications. Existing treatment options are largely palliative, and systemic disease burden remains substantially unaddressed by topical wound-care approaches. The condition has already attracted regulatory attention: a topical gene therapy for RDEB received FDA approval in 2023, but systemic options remain limited, leaving a meaningful gap that INmune Bio is targeting.

Global registration sequence

The EMA filings sit within a sequenced, three-jurisdiction registration strategy. INmune Bio is targeting a UK MHRA MAA submission in Q4 2026, followed by the EU MAA and a US Biologics License Application, both planned for Q1 2027. The company said EU orphan designation, if granted and retained through approval, would carry 10 years of EU market exclusivity under applicable European orphan medicine rules, mirroring the orphan drug designation the programme already holds in the United States.

Chief executive David Moss framed the submissions as execution milestones rather than clinical inflection points, saying the company's focus is on "converting the clinical, regulatory and manufacturing progress achieved to date into a defined sequence of registration milestones across the UK, European Union and United States."

Ebstrocel is drawn from INmune Bio's CORDStrom platform, which uses pooled, allogeneic umbilical cord-derived mesenchymal stromal cells. Pooling from multiple donors is intended to reduce the batch-to-batch variability that has historically constrained allogeneic cell therapies, and the company's semi-automated, fully closed manufacturing process is designed to support scalable, off-the-shelf supply. Chief scientific officer Mark Lowdell, inventor of the platform, described RDEB as "a systemic disease with substantial unmet need beyond the visible manifestations of skin injury" and positioned Ebstrocel as an opportunity to demonstrate that a pooled stromal cell platform can navigate late-stage regulatory development.

Market context and competitive landscape

The allogeneic cell therapy field has gained significant momentum over recent years as developers seek to move away from autologous manufacturing constraints. Mesenchymal stromal cell programmes have had a historically mixed regulatory record, particularly in the United States, where several pivotal trials failed to replicate earlier efficacy signals. INmune Bio's pooling strategy is an attempt to address that variability problem at source, though regulators will expect robust comparability and potency data across donor pools before granting approval.

In rare dermatological conditions more broadly, the EMA has shown willingness to engage constructively with sponsors through scientific advice, and the orphan framework provides meaningful commercial protection for products that succeed. For INmune Bio, the CORDStrom platform has value beyond RDEB: the company has stated that progress with Ebstrocel is intended to de-risk and inform pipeline extensions into other indications, making the upcoming regulatory interactions strategically significant for the broader platform thesis.

With the UK submission targeted for the end of 2026 and transatlantic filings to follow in early 2027, the next twelve months represent the most consequential regulatory period in the company's history. Investors will be watching for the EMA's response on orphan designation, which typically takes around 90 days from submission, as an early indicator of the European pathway's viability.